Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BXSY Form 4's
Thomas Winmill comes into March like a Lion, gobbling up more shares of Bexil Investment Trust. From February 27th through March 6th Winmill added 23,363shares, bringing his share total to a whopping 51,078.
2/27/24: https://www.otcmarkets.com/filing/html?id=17317059&guid=-6d-kK8gFBizlLh
2/29/24: https://www.otcmarkets.com/filing/html?id=17331033&guid=-6d-kK8gFBizlLh
3/04/24: https://www.otcmarkets.com/filing/html?id=17342421&guid=-6d-kK8gFBizlLh
3/06/24: https://www.otcmarkets.com/filing/html?id=17351892&guid=-6d-kK8gFBizlLh
Pacific Valley Bancorp declared a 10% stock dividend
Pacific Valley Bancorp PVBK today announced that the Board of Directors declared a 10% stock dividend payable on April 15, 2024 to shareholders of record as of the close of business on March 28, 2024. The dividend will be issued in the form of additional shares of common stock. Fractional shares will be rounded up to the nearest whole share of stock.
https://www.otcmarkets.com/stock/PVBK/news/Pacific-Valley-Bancorp-Announces-Stock-Dividend?id=431821
Bexil Investment Trust, 2023 Annual Report (BXSY)
BXSY: 2023 Annual Report
$BWVI: What %%% is his Buy Call up now?
Hmmmm it will be exciting to see what steps are being taken by our newly appointed neurosurgical CEO Dr. Jha and his fellow neurosurgeon Dr. Bailes.
"The Company believes that the steps now being taken will enable the Company to maximize future opportunities and compete more effectively with significantly less debt on the balance sheet and more capital for growth."
https://www.accesswire.com/825669/psycheceutical-bioscience-strategically-pivots-into-the-brain-computer-interface-bci-space
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
MIAMI, FL / ACCESSWIRE / January 17, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of neurological treatments, appointed Neilank K. Jha, MD, Executive Chairman and CEO on November 1, 2023 to initiate an immediate turnaround to avert restructuring for operational, financial and regulatory reasons.
https://www.accesswire.com/825669/psycheceutical-bioscience-strategically-pivots-into-the-brain-computer-interface-bci-space
We have two well connected neurosurgeons leading the way here for Neuraseed/Psycheceutical. Certainly a huge connection here with the Nico Corporation.
12/12/23 Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
https://finance.yahoo.com/news/dr-neilank-jha-appointed-executive-140000521.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACKH1iEj3iRSMnGszxv7S6uBOHQSxox2acRNuIZZt83Sg0OM_vBYNMCT1hFH3d0e1IUe5qebJXcZu-l360MRc9VP_5f4-XLnOouHCryUGKVaXG8Y34XDQRsG2IOZueYJ0rNWhP-yUW44nLwHtAfH8SejDdk9niVTGRpz5ikuFrmi
Interesting informational podcast further reinforcing the connection between Dr. Bailes and the Nico Corporation. Additionally, a social media post supplementing the aforementioned connection.
Podcast: Neural Implant Podcast
Social Media: Linkedin post, Nico Corporation/Dr. Julian Bailes
Where's our VWAP? I need to stay informed here!
$DNIF Form 4
Thomas Winmill adds another 800 shares
https://archive.fast-edgar.com/20231215/A7ZZ222CZ22232Y2222S22Z2HNGNZL2S2H52/
Fidelity
($DNIF) ROCHESTER, NY – December 1, 2023 – A quarterly distribution of $0.25 per share was declared today by Dividend and Income Fund (Stock Symbol: DNIF) (Net Asset Value Symbol: XDNIX) (the “Fund”), payable December 28, 2023 to shareholders of record as of December 15, 2023 (ex-dividend date: December 14, 2023)
https://dividendandincomefund.com/main/wp-content/uploads/2023/12/231201-Dividend-and-Income-Fund-Declares-December-2023-Quarterly-Distribution.pdf
$DNIF Form 4
Thomas Winmill adds another 1,090 Shares to his pile of 26,915
https://www.otcmarkets.com/filing/html?id=17089136&guid=R7J-kWJTTD7-B3h
What's going on with this thing? It trades like a community bank that is 10-20 times bigger than it is... it's very strange. I've been in it for years... Where are you seeing the DTC Chill? I've never seen that before... It trades on the highest tier of the OTC market so I can imagine there being much wrong with it.
$DNIF Form 4
Thomas Winmill adds another 570 shares to his total pile of 25,825.
https://www.otcmarkets.com/filing/html?id=17082389&guid=NsJ-kKqjA3cmB3h
$DNIF Fund Manager and CEO Thomas Winmill
https://dividendandincomefund.com/fund-manager
$DNIF Trading at a 36% discount to NAV
$DNIF Form 4 posted after hours today. Thomas Winmill CEO, Chief Legal Officer, President , filed for the past 3 trading sessions, starting last Friday 11/17/23.
https://archive.fast-edgar.com/20231121/A7Z2222CH2223222222U22Z2HNGNC22I2252/
The Holding Company reported a consolidated net profit of $729,000 for the nine-months ended
September 30, 2023, compared to reporting a combined net loss of $236,000 for the nine-months
ended September 30, 2022.
https://www.otcmarkets.com/otcapi/company/dns/news/document/70287/content
The Holding Company reported a consolidated net profit of $503,000 for the six-months ended
June 30, 2023, compared to reporting a combined net loss of $745,000 for the six-months ended
June 30, 2022.
They purchased new equipment in 2022 which was a big strain on profits. 2023 has been quite good so far. In addition Book Value is well over $6 a share.
https://www.otcmarkets.com/otcapi/company/dns/news/document/68755/content
You're off base here.
I'm almost 100% confident he posts negativity to play the stock. He accumulates the dips then sells on the uptrend and when he wants to reload and play again he shows up again, trash talks and tries to do the same thing over and over. Notice how he disappeared for quite some time while this thing has bounced off that low of 7's. He'll say anything to try and convince naive people to sell the stock and feed his game. That's what I'm convinced of. Everyone has their method... I'm right there with you Big Cat, he's super annoying and will post anything to discredit any ticker.
Ultimately he's not really worth our time.
$BWVI
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
MIAMI, FL / ACCESSWIRE / August 10, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the completion of dosing of the first cohort of subjects in a Phase I clinical trial of its patented NeuroDirect™ topical ketamine formulation for the treatment of Post Traumatic Stress Disorder (PTSD). NeuroDirect ketamine is the company's lead non-systemic drug candidate designed to target free nerve endings at the back of the neck, with the objective of delivering ketamine safely, effectively and without hallucinogenic effects.
Key results from first cohort include:
The topical administration of the NeuroDirect ketamine was shown to be safe and well-tolerated.
No clinically relevant adverse events or psychotomimetic effects were seen, giving the Safety Review Committee confidence to proceed with an escalation of the dosage for the second cohort. The viability of topical administration was confirmed when anticipated pharmacokinetics (PK) aligned well with the observed PK parameters in cohort 1, bolstering confidence for replication with increased dosage in cohort 2.
"We are excited about the overall success of our first cohort from our Phase I clinical trial," said Chad Harman, CEO of Psycheceutical. "The favorable safety profile for our topical NeuroDirect ketamine represents an exciting milestone in our goal of bringing to market a novel method for treating mental health and neurodegenerative diseases. We look forward to expanding our drug pipeline with other psychedelic compounds using this novel delivery method in the near future."
Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder. The goal of the Phase I study, which is being conducted by iNGENu Pty Ltd. in Australia, is to test the safety, tolerability, and pharmacokinetics of NeuroDirect ketamine in 24 healthy adult participants. The company's first cohort included six trial participants who were given a topical dose of NeuroDirect ketamine and underwent a thorough safety assessment for 12 days. Topical ketamine was shown to be safe and well-tolerated for all cohort 1 participants. This data gave the trial's Safety Review Committee assertive confidence to proceed with an increased dosage for cohort 2. Full details on the clinical trial can be found here.
NeuroDirect ketamine is the first of several opportunities in the company's drug pipeline designed to treat mental health and neurodegenerative disorders. Psycheceutical's delivery technologies have been featured in numerous publications including Forbes, BioSpace, Pharmacy Times, Drug Development & Delivery, Genetic Engineering & Biotechnology News, Benzinga, and more. The company was recently named a Top 10 Biotech Startup for 2023 by Life Sciences Review. The company has attracted the attention of investors like Kevin Harrington from Shark Tank and the Chief Medical Officer is neurosurgeon Dr. Julian Bailes who was portrayed by Alec Baldwin in the movie Concussion.
https://www.accesswire.com/773524/Psycheceutical-Announces-Successful-First-Cohort-Dosing-Moves-to-Dose-Escalation-in-Phase-I-Trial-of-NeuroDirect-Ketamine-for-PTSD
Love all the clickable information packed links in the PR! Good stuff mang! Peace Big Cat.
Sweet... Psycheceutical is gonna be there. That's the conference in Denver this weekend, getting all the Hype.
Cool that Rodgers will be there. Texas governor Rick Perry gonna be there as well... interesting a Republican governor advocating for psychedelics... that's definitely a great thing!
Good Morning Psycheceutical cats! I’m looking forward to the gigantic possibilities and growth of this acorn of a company.
Indeed Salty. It's been interesting to witness. I hold a couple small banks in my portfolio right now and one of these two is getting beat down rather severely... All I can think is, it's an opportunity to add at blockbuster prices. What do you think Big Cat?
joey
Amongst all the bank turmoil the past week or two this one has held up quite nicely. There was certainly some larger transactions that took place at the 3.50-3.60 level, but someone was clearly willing to soak them up.
Sheesh... all this bank turmoil has really laid the smack down on this one.
Opportunities?
Simply build a legit company and the investors will follow.
It certainly got interesting.
Some gifts being given here!
You missed part of the year if you believe that. ??
Great NEWS here, and the big grabs of shares in this range continues.
SKAS $4.50 X $4.72
You know it’s on if that offer gets gobbled at $4.72!
SKAS has been getting devoured in this $3.80-4.20 range.
CDEL sitting at $2.80 for 35,000 shares. ($98,000)
Only 675 shares left there at 4.20, it’s been gettin’ beat on all day.
The offers keep gettin’ gobbled up here. Would be nice to see a positive year end report and watch this thing just bull charge past the $5 level.